Methods and compositions for treating non-small cell lung cancer comprising an anti tigit antagonist antibody and a PD-1 axis binding antagonist
WO2025049277A9 Publication Date: 2025-05-22GENENTECH INC
0 Cites 0 Cited by
Patent Information
- Application Number
- PCT/US2024/043565
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-08-25
- Filing Date
- 2024-08-23
- Publication Date
- 2025-05-22
AI Technical Summary
Technical Problem
There is a significant need for novel, effective adjuvant therapies for patients with non-small cell lung cancer (NSCLC) following surgical resection, as 30%-70% of patients develop recurrence and die due to disease progression.
Method used
Administering one or more dosing cycles of tiragolumab and atezolizumab, either following complete resection and adjuvant chemotherapy, or as part of an adjuvant chemotherapy regimen, to treat NSCLC patients.
Benefits of technology
The combination of tiragolumab and atezolizumab has been shown to increase disease-free survival and overall survival in NSCLC patients, providing a potential solution to the high recurrence rates post-surgical resection.
✦ Generated by Eureka AI based on patent content.
Abstract
The present disclosure relates to the treatment of non-small cell lung cancer (NSCLC). More specifically, the disclosurerelates to the treatment of patients having an NSCLC by administering a treatment regimen that includes an anti-TIGIT antagonist antibody (e.g., tiragolumab) and a PD-1 axis binding antagonist (e.g., atezolizumab) following surgical resection and adjuvant chemotherapy or by administering a treatment regimen that includes an adjuvant chemotherapy, an anti-TIGIT antagonist antibody (e.g., tiragolumab), and a PD-1 axis binding antagonist (e.g., atezolizumab) following surgical resection.
Need to check novelty before this filing date? Find Prior Art